Advertisement

Academic Psychiatry

, Volume 36, Issue 2, pp 118–121 | Cite as

Impact of a Metabolic Screening Bundle on Rates of Screening for Metabolic Syndrome in a Psychiatry Resident Outpatient Clinic

  • Ilse R. Wiechers
  • Mark Viron
  • Joseph Stoklosa
  • Oliver Freudenreich
  • David C. Henderson
  • Anthony Weiss
Brief Report

Abstract

Objective

Although it is widely acknowledged that second-generation antipsychotics are associated with cardiometabolic side effects, rates of metabolic screening have remained low. The authors created a quality-improvement (QI) intervention in an academic medical center outpatient psychiatry resident clinic with the aim of improving rates of screening for metabolic syndrome in patients being prescribed antipsychotic medications.

Methods

The core components of the QI intervention included resident education and creation of a metabolic screening bundle for the electronic medical record. Quarterly audits of individual patient electronic medical records assessed whether a patient was currently prescribed antipsychotics and whether metabolic-syndrome screening had been documented at any time in the preceding 12 months.

Results

In each audit period, from 131 to 156 patients (30%–36% of total clinic sample) were prescribed antipsychotic medication. After the intervention, rates of documentation of the components of the metabolic screening bundle increased between 3.5- and 10-fold (final rates: 39% for blood pressure, 44% for BMI, and 55% for glucose and lipid panel). Rates of documenting the full bundle increased nearly 30-fold (final rate: 31%).

Conclusion

Provider-education combined with introduction of a documentation bundle in the electronic medical record increased rates of documented metabolic screening in patients being prescribed antipsychotic medications by psychiatry residents.

Keywords

Antipsychotic Medication Academic Psychiatry Psychiatry Resident Quality Improvement Intervention Metabolic Screening 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Newcomer JW: Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 2007; 68(suppl.1):20–27PubMedGoogle Scholar
  2. 2.
    Grundy SM, Brewer HB, Cleeman JL, et al: Definition of the metabolic syndrome: report of the National Heart, Lung, and Blood Institute/Am Heart Assoc. Conference on Scientific Issues Related to Definition. Circulation 2004; 109:433–438PubMedCrossRefGoogle Scholar
  3. 3.
    American Diabetes Association & American Psychiatric Association: Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care 2004; 27:596–601CrossRefGoogle Scholar
  4. 4.
    Marder SR, Essock SM, Miller AL, et al: Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161:1334–1349PubMedCrossRefGoogle Scholar
  5. 5.
    Goff DC, Cather C, Evins AE, et al: Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry 2005; 66:183–194PubMedCrossRefGoogle Scholar
  6. 6.
    Buckley PF, Miller D, Singer B, et al: Clinicians’ recognition of the metabolic adverse effects of antipsychotic medications. Schizophr Res 2005; 79:281–288PubMedCrossRefGoogle Scholar
  7. 7.
    Barnes TRE, Paton C, Hancock E, et al: Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics: a quality-improvement programme. Acta Psychiatr Scand 2008; 118:26–33PubMedCrossRefGoogle Scholar
  8. 8.
    Mackin P, Bishop DR, Watkinson HMO, et al: A prospective study of monitoring practices for metabolic disease in anti-psychotic-treated community psychiatry patients. BMC Psychiatry 2007; 7:28PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Haupt DW, Rosenblatt LC, Kim E,et al: Prevalence and predictors of lipid and glucose monitoring in commercially-insured patients treated with second-generation antipsychotic agents. Am J Psychiatry 2009; 166:345–353PubMedCrossRefGoogle Scholar
  10. 10.
    Berenholtz SM, Milanovich S, Faricloth A, et al: Improving care for the ventilated patient. Jt Comm J Qual Saf 2004; 30:195–204PubMedGoogle Scholar

Copyright information

© Academic Psychiatry 2012

Authors and Affiliations

  • Ilse R. Wiechers
    • 1
    • 2
  • Mark Viron
    • 1
    • 3
  • Joseph Stoklosa
    • 1
    • 4
  • Oliver Freudenreich
    • 1
  • David C. Henderson
    • 1
  • Anthony Weiss
    • 1
  1. 1.Dept. of PsychiatryMassachusetts General HospitalBoston
  2. 2.Dept. of PsychiatryYale School of MedicineUSA
  3. 3.Viron is with the Massachusetts Mental Health CenterUSA
  4. 4.Stoklosa is with McLean HospitalUSA

Personalised recommendations